



April 7, 2022

**BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards, launch of Merzee® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, in the US market, under exclusive license, marketing and distribution agreement with Slayback Pharma LLC.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**



**Encl: a/a**

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin Launches Merzee® Capsules in the United States

**Mumbai, Baltimore, April 07, 2022:** Global pharma major Lupin Limited (Lupin) today announced that it has launched Merzee® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, in the US market, under exclusive license, marketing and distribution agreement with Slayback Pharma LLC (Slayback). Slayback had earlier launched this product in the US in February 2021.

Merzee® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Taytulla® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg of Allergan Pharmaceuticals International Limited.

Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1 mg/20 mcg (RLD: Taytulla®) had estimated annual sales of USD 90 million in the U.S. (IQVIA MAT February 2022).

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue in research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

### About Slayback

Slayback Pharma is a Princeton, NJ headquartered, specialty pharmaceutical company focused on the development and commercialization of complex, high-value ANDAs and patent-protected NDAs that address meaningful unmet needs. Slayback has 116 employees, including over 75 in R&D who are located in its office and state-of-the-art R&D laboratory in Hyderabad, India. The company is backed by highly-regarded private equity investors, KKR and Everstone, who committed \$60 million and \$50 million in financing in December 2016 and December 2019 respectively. In Slayback's short history, the company has built a differentiated, robust pipeline, while achieving consistent success in PIV-related patent litigations and earning seven exclusivities (six sole first-to-files and two competitive generic therapies).

**Press Release**



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

**For further information or queries please contact –**

**Shweta Munjal**

Vice President & Global Head – Corporate Communications

Email: [shwetamunjal@lupin.com](mailto:shwetamunjal@lupin.com)

**\*Safe Harbor Statement**

Taytulla® is a registered trademark of Allergan Pharmaceuticals International Limited.